Current biodetection assays that employ monoclonal antibodies as primary capture agents exhibit limited
fieldability, shelf life, and performance due to batch-to-batch production variability and restricted thermal stability. In
order to improve upon the detection of biological threats in fieldable assays and systems for the Army, we are
investigating protein catalyzed capture (PCC) agents as drop-in replacements for the existing antibody technology
through iterative in situ click chemistry. The PCC agent oligopeptides are developed against known protein epitopes and
can be mass produced using robotic methods. In this work, a PCC agent under development will be discussed. The
performance, including affinity, selectivity, and stability of the capture agent technology, is analyzed by
immunoprecipitation, western blotting, and ELISA experiments. The oligopeptide demonstrates superb selectivity
coupled with high affinity through multi-ligand design, and improved thermal, chemical, and biochemical stability due
to non-natural amino acid PCC agent design.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.